Avalon GloboCare Corp. (NASDAQ:CHGA) Sees Significant Drop in Short Interest

Posted by Lindsey Winhoffer on Sep 29th, 2026

Avalon GloboCare Corp. (NASDAQ:CHGA – Get Free Report) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 33,188 shares, a drop of 51.8% from the August 31st total of 68,808 shares. Based on an average daily volume of 48,548 shares, the short-interest ratio is presently 0.7 days. Approximately 3.9% of the company’s shares are sold short.

Avalon GloboCare Stock Down 3.0%

Shares of NASDAQ CHGA traded down $0.06 during trading on Tuesday, reaching $1.92. 21,002 shares of the company traded hands, compared to its average volume of 198,308. Avalon GloboCare has a 52-week low of $1.79 and a 52-week high of $49.20. The stock has a market capitalization of $2.15 million, a PE ratio of -0.14 and a beta of -0.05. The firm has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $6.59.

Avalon GloboCare (NASDAQ:CHGA – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($2.80) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on CHGA

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare Corp. is a life sciences company focused on developing cell-based technologies and precision medicine applications. Its work has included regenerative medicine, cancer diagnostics, and therapeutic platforms designed to support the development of personalized healthcare treatments.

The company has also pursued technologies involving cellular processing, biomanufacturing, and related laboratory services. Avalon GloboCare’s activities have included collaborations and development programs intended to translate emerging cell and molecular science into clinical and commercial applications.

Avalon GloboCare was established in the mid-2010s and has been headquartered in Freehold, New Jersey.